^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    TA-MUC1 positive

    i
    Other names: MUC1, ADMCKD, ADMCKD1, CD227, MCD, MCKD, MCKD1, PEM, PUM, Mucin 1, cell surface associated, Cancer antigen 15-3
    Entrez ID:
    4582
    Related biomarkers:
    Expression
    Others
    3ms
    GT-00AxIL15, a Novel Tumor-Targeted IL-15-Based Immunocytokine for the Treatment of TA-MUC1-Positive Solid Tumors: Preclinical In Vitro and In Vivo Pharmacodynamics and Biodistribution Studies. (PubMed, Int J Mol Sci)
    These results support the rationale to improve PK and anti-tumor efficacy of IL-15 by increasing local concentrations at the tumor site via conjugation to a TA-MUC1 binding mAb. The tumor-selective expression pattern of TA-MUC1, powerful immune activation and anti-tumor cytotoxicity, long serum half-life and tumor targeting properties, render GT-00AxIL15 a promising candidate for treatment of solid tumors with high medical need, e.g., ovarian, lung and breast cancer.
    PK/PD data • Preclinical • Journal
    |
    CD8 (cluster of differentiation 8) • MUC1 (Mucin 1) • IL15 (Interleukin 15)
    |
    TA-MUC1 positive
    |
    GT-00A x IL15
    2years
    Preclinical characterization of GT-00A x IL15: A novel IL-15-based immunocytokine with unique tumor targeting properties (AACR 2022)
    Our results show that by using TA-MUC1 as a broadly expressed and highly tumor-specific antigen, we are able to direct IL-15 to the tumor. Local enrichment of GT-00A x IL15 within the tumor ultimately induced local effector cell activation and expansion. GT-00A x IL15 showed single agent efficacy in vivo with a good safety profile.
    Preclinical
    |
    CD8 (cluster of differentiation 8) • MUC1 (Mucin 1) • IL15 (Interleukin 15)
    |
    MUC1 expression • TA-MUC1 positive
    |
    GT-00A x IL15
    over2years
    Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study. (PubMed, ESMO Open)
    Gatipotuzumab switch maintenance therapy does not improve outcome in TA-MUC1-positive ovarian cancer patients.
    Clinical • P2 data • Journal
    |
    MUC1 (Mucin 1) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    TA-MUC1 positive
    |
    PankoMab-GEX (gatipotuzumab)